TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3881104

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg/day and Propranolol 240 mg/day combined
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31651321

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention comprising education about dementia, counselling and group sessions
Number of subjects: 208

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 208
Study: 29985236

Group type: EXPERIMENTAL
Intervention: Critical Administration Threshold (CAT+), defined as 3 U or greater RBC in the first hour
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Resuscitation Intensity (RI4+), defined as 4 U or greater total products in the first 30 minutes
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Resuscitation Intensity (RI) as a continuous variable
Number of subjects: 680

Group type: COMPARATOR
Intervention: Comparison of CAT+ and RI4+
Number of subjects: 680
Study: 24915543

Group type: EXPERIMENTAL
Intervention: Low-dose fish oil (2.4 g/day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-dose fish oil (16.2 g/day)
Number of subjects: 14
Study: 24382614

Group type: EXPERIMENTAL
Intervention: Inhalation of 100% lavender oil (3 mL in a glass jar at bedside from 10 pm to 6 am)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Inhalation of 100% lavender oil
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study: 22239862

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg once daily
Number of subjects: 1581

Group type: EXPERIMENTAL
Intervention: Flibanserin 50 mg twice daily
Number of subjects: 1581

Group type: EXPERIMENTAL
Intervention: Flibanserin 25 mg twice daily
Number of subjects: 1581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1581
Study: 19207432

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using indocyanine green (ICG) dye with a diode laser
Number of subjects: 16
Study: 17502777

Group type: EXPERIMENTAL
Intervention: Intramuscular biperiden
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 30
Study: 14982808

Group type: EXPERIMENTAL
Intervention: Albendazole formulations with arachis oil‐polysorbate 80
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole formulations with hydroxypropyl‐beta‐cyclodextrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macrogol suppositories
Number of subjects: 0
Study: 12466924

Group type: EXPERIMENTAL
Intervention: Primary task with varying S-R compatibility
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extra memory task (Experiment 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increasing number of S-R alternatives in primary task (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inconsistency of previously used S-R mappings (Experiment 4)
Number of subjects: 0
Study: 9655655

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty
Number of subjects: 135

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 135
Study: 8587078

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (3 g/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2568327

Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine nightly
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: 2 X 150 mg nizatidine daily
Number of subjects: 242

Group type: COMPARATOR
Intervention: 2 X 150 mg ranitidine daily
Number of subjects: 242
Study: 59013

Group type: EXPERIMENTAL
Intervention: Raised maternal plasma-urate concentrations
Number of subjects: 332

Group type: COMPARATOR
Intervention: Maternal hypertension without hyperuricaemia
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Mild maternal hypertension with severe hyperuricaemia
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Plasma-urate measurements
Number of subjects: 332
Study: 31226388

Group type: EXPERIMENTAL
Intervention: Intelligent liver function testing (iLFT)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 554
Study: 28096535

Group type: EXPERIMENTAL
Intervention: Germline single-nucleotide polymorphisms (SNPs) associated with relapse
Number of subjects: 2225

Group type: EXPERIMENTAL
Intervention: Germline SNPs associated with rapid drug clearance or drug resistance
Number of subjects: 2225

Group type: COMPARATOR
Intervention: Model without SNPs for black ancestry
Number of subjects: 2225

Group type: EXPERIMENTAL
Intervention: Model with SNPs for black ancestry
Number of subjects: 2225

Group type: COMPARATOR
Intervention: Model without SNPs for Hispanic ancestry
Number of subjects: 2225

Group type: EXPERIMENTAL
Intervention: Model with SNPs for Hispanic ancestry
Number of subjects: 2225

Group type: EXPERIMENTAL
Intervention: Asparaginase resistance or allergy SNPs in treatment arms
Number of subjects: 2225
Study: 24671237

Group type: EXPERIMENTAL
Intervention: GOS-containing infant formula (0.44 g/dl of GOS)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Control formula without GOS
Number of subjects: 365
Study: 23616564

Group type: EXPERIMENTAL
Intervention: Prism adaptation with background movement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prism adaptation
Number of subjects: 0
Study: 21988774

Group type: EXPERIMENTAL
Intervention: Community-Based Health Insurance scheme
Number of subjects: 0
Study: 19249633

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading, 10 mg maintenance)
Number of subjects: 3534

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading, 75 mg maintenance)
Number of subjects: 3534
Study: 17259812

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 (approximately 5x10^10)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15294376

Group type: EXPERIMENTAL
Intervention: Rofecoxib, 25mg per day for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11108307

Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF 5 microg/kg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF 10 microg/kg/day
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: PEG-rHuMGDF 25 microg/kg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All treatment groups (including placebo)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All dosages of PEG-rHuMGDF
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 33
Study: 9512875

Group type: EXPERIMENTAL
Intervention: Amiloride hydrochlorothiazide (5/50 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine (40 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/d)
Number of subjects: 20
Study: 8457046

Group type: EXPERIMENTAL
Intervention: Sufentanil (15 micrograms/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fentanyl (150 micrograms/min)
Number of subjects: 24
Study: 2429095

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and atenolol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29718967

Group type: EXPERIMENTAL
Intervention: Bedaquiline 400 mg alone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bedaquiline 400 mg plus Rifampin 600 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bedaquiline 400 mg plus Rifabutin 300 mg
Number of subjects: 33
Study: 27236272

Group type: EXPERIMENTAL
Intervention: AKB‐9778 monotherapy: subcutaneous AKB‐9778 15 mg BID + monthly sham intraocular injections
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combination therapy: subcutaneous AKB‐9778 15 mg BID + monthly 0.3 mg ranibizumab
Number of subjects: 144

Group type: COMPARATOR
Intervention: Ranibizumab monotherapy: subcutaneous placebo injections BID + monthly 0.3 mg ranibizumab
Number of subjects: 144
Study: 25614407

Group type: EXPERIMENTAL
Intervention: Infraclavicular catheter
Number of subjects: 50

Group type: COMPARATOR
Intervention: Supraclavicular catheter
Number of subjects: 50
Study: 24120712

Group type: EXPERIMENTAL
Intervention: Oseltamivir (75 mg b.i.d. for 5 days)
Number of subjects: 1709
Study: 21775146

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day for the first 3 days, then 300 mg/day for a further 2 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 40
Study: 18815953

Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy (IPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 0
Study: 16546843

Group type: EXPERIMENTAL
Intervention: Doxazosin (4 mg/day for 2 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (untreated hypertensive patients)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (normotensive subjects)
Number of subjects: 10
Study: 12704402

Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet (27% of energy as protein, 45% as carbohydrate)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lower-Protein (LP) diet (16% of energy as protein, 57% as carbohydrate)
Number of subjects: 36
Study: 9878015

Group type: EXPERIMENTAL
Intervention: Triple combination drug therapy with indinavir, zidovudine, and lamivudine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Triple combination drug therapy after either indinavir or zidovudine-lamivudine treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Prolonged indinavir-zidovudine-lamivudine treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (zidovudine plus lamivudine or zidovudine alone)
Number of subjects: 27
Study: 8529495

Group type: EXPERIMENTAL
Intervention: Pre-filled insulin pen (NovoLet)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional syringes
Number of subjects: 60
Study: 1958856

Group type: EXPERIMENTAL
Intervention: Beta-carotene 30 mg/day plus retinyl palmitate 25,000 IU/day
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6105
Study: 6759062

Group type: EXPERIMENTAL
Intervention: Ciramadol 20 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ciramadol 30 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ciramadol 40 mg
Number of subjects: 34
Study: 30920975

Group type: EXPERIMENTAL
Intervention: Silymarin 140 mg/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU/day
Number of subjects: 150

Group type: COMPARATOR
Intervention: Lifestyle plus placebo
Number of subjects: 150
Study: 27659294

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day until disease progression or unacceptable toxicity
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day
Number of subjects: 102
Study: 25662553

Group type: EXPERIMENTAL
Intervention: Bioadhesive chlorhexidine gel 0.2%
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 7
Study: 23115078

Group type: EXPERIMENTAL
Intervention: Energy Deficit (exercise group)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (non-exercising group)
Number of subjects: 21
Study: 21946712

Group type: EXPERIMENTAL
Intervention: ZeroFly® insecticide incorporated plastic sheeting (deltamethrin 2.0 g/kg or 265 mg/m2)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Untreated plastic sheets (control)
Number of subjects: 250
Study: 19536922

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16754759

Group type: EXPERIMENTAL
Intervention: Team Solutions intervention (24-week psychoeducational group focused on illness management)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 71
Study: 15544683

Group type: EXPERIMENTAL
Intervention: Package (booklet and 15‐min video)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (booklet on living with cancer)
Number of subjects: 65
Study: 11822998

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg four times daily for 10 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 41
Study: 9661546

Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg (maximal dose 25 mg)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 130
Study: 7631610

Group type: EXPERIMENTAL
Intervention: Noninvasive BRS measurement
Number of subjects: 40

Group type: COMPARATOR
Intervention: Invasive BRS measurement
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Noninvasive technique after phenylephrine injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Invasive technique after phenylephrine injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Noninvasive BRS value < 4.0 ms/mm Hg
Number of subjects: 40
Study: 2239887

Group type: EXPERIMENTAL
Intervention: Endoscopic endoprosthesis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 50
Study: 320832

Group type: EXPERIMENTAL
Intervention: Coated, rapidly dissolving lithium carbonate tablets
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Medium-slow-release lithium sulphate tablets
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Slow-release lithium sulphate tablets
Number of subjects: 27
Study: 6182175

Group type: EXPERIMENTAL
Intervention: mianserin 10 mg 3 times daily for 1 week followed by 60 mg mianserin daily for a second week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: amitriptyline 25 mg 3 times daily for 1 week followed by 150 mg amitriptyline daily for a second week
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo treatment for 14 days
Number of subjects: 20
Study: 30581109

Group type: EXPERIMENTAL
Intervention: Global Longitudinal Strain (GLS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Global Circumferential Strain (GCS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Global Radial Strain (GRS)
Number of subjects: 100
Study: 28925034

Group type: EXPERIMENTAL
Intervention: 3.14% dipotassium oxalate monohydrate-containing strip (self-applied)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3.14% dipotassium oxalate monohydrate-containing strip (professionally applied)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3.14% dipotassium oxalate monohydrate-containing strip (self-applied and professionally applied)
Number of subjects: 60
Study: 26555871

Group type: EXPERIMENTAL
Intervention: Tizanidine 4 mg orally 1 hour before surgery and twice daily during the first postoperative week
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24826894

Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion policy (counts <10 × 10(9) /L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 0
Study: 22842177

Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day Fungisome
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day Fungisome
Number of subjects: 65

Group type: COMPARATOR
Intervention: 1 mg/kg/day conventional amphotericin B
Number of subjects: 65
Study: 20146627

Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine plus efavirenz (arm 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine plus atazanavir-ritonavir (arm 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tenofovir-emtricitabine plus zidovudine-abacavir (arm 3)
Number of subjects: 30
Study: 17650789

Group type: EXPERIMENTAL
Intervention: Yiguan Decoction (YGD) plus NP protocol of chemotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: NP protocol of chemotherapy
Number of subjects: 92
Study: 15691685

Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 300

Group type: COMPARATOR
Intervention: CABG with CPB
Number of subjects: 300
Study: 11844942

Group type: EXPERIMENTAL
Intervention: Comprehensive treatment programme with hypnosis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comprehensive treatment programme without hypnosis
Number of subjects: 45
Study: 10825859

Group type: EXPERIMENTAL
Intervention: Experimental essential oil‐containing dentifrice
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 42
Study: 8703662

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cimetidine plus terfenadine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2313527

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine gluconate irrigation
Number of subjects: 222

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine rinse (positive control)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Water irrigation (irrigation control)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice (negative control)
Number of subjects: 222
Study: 7444376

Group type: EXPERIMENTAL
Intervention: 600 mg of calciumacetylsalicylic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg of calciumacetylsalicylic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated doses of 100 mg of calciumacetylsalicylic acid at 12 h intervals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 12 h 100 mg doses of calciumacetylsalicylic acid (equal to 80 mg of aspirin)
Number of subjects: 0
Study: 29730601

Group type: EXPERIMENTAL
Intervention: Immediate endoscopy with haemostatic powder application within 2 hours of admission
Number of subjects: 86

Group type: COMPARATOR
Intervention: Early elective endoscopy only (control group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Immediate powder application
Number of subjects: 86
Study: 27828791

Group type: EXPERIMENTAL
Intervention: Vernakalant (3 mg/kg infusion for 10 minutes, followed by 2 mg/kg infusion for 15 minutes if needed)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo (infusion for 10 minutes, followed by placebo infusion for 15 minutes if needed)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Vernakalant and Placebo
Number of subjects: 123
Study: 25700947

Group type: EXPERIMENTAL
Intervention: CDP-choline (500mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CDP-choline (1000mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24180554

Group type: EXPERIMENTAL
Intervention: Polyp Specific Polymer analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colonoscopy and histology examination
Number of subjects: 0
Study: 20624152

Group type: EXPERIMENTAL
Intervention: Supplementation with docosahexaenoic acid (DHA) and arachidonic acid (AA) - 0.5 mL oil (32 mg DHA and 31 mg AA) per 100 mL milk from 1 week after birth until discharge (9 weeks on average)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (no DHA and AA)
Number of subjects: 92
Study: 19494788

Group type: EXPERIMENTAL
Intervention: Erlotinib 1400 mg weekly on days 2, 9, and 16 plus Pemetrexed 500 mg/m every 21 days (arm A)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Erlotinib 250 mg on days 2 to 16 plus Pemetrexed 500 mg/m every 21 days (arm B)
Number of subjects: 42
Study: 17765461

Group type: EXPERIMENTAL
Intervention: Early computed tomography (CT) examination
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard practice (SP) - supine abdominal and erect chest radiography
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 205
Study: 14742841

Group type: COMPARATOR
Intervention: Calcium (1.2 g/d) and vitamin D (8 microg/d) supplementation for 6 months in RYGB women with low bone mass, n = 13
Number of subjects: 44

Group type: COMPARATOR
Intervention: RYGB women
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control women (CNT), n = 65
Number of subjects: 44
Study: 11387860

Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Declaration of Helsinki
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Belmont Report
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethical principle of fidelity
Number of subjects: 0
Study: 9396449

Group type: EXPERIMENTAL
Intervention: Short pulse durations (2, 3, 4, 6 ms)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Long pulse durations (6, 12, 18 ms)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Short and long pulse durations
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Stored energy at defibrillation threshold
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mean current over the full range of pulse durations
Number of subjects: 29
Study: 8126716

Group type: EXPERIMENTAL
Intervention: Comprehensive prevention program
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Refusal skills training
Number of subjects: 389
Study: 2446081

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritanserin (20 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritanserin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0
Study: 31426829

Group type: EXPERIMENTAL
Intervention: Intra-operative CT scanning
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intra-operative CT scanning (Control)
Number of subjects: 0